Inhibitory effects of low molecular weight heparin on mediator release by mast cells: Preferential inhibition of cytokine production and mast cell- dependent cutaneous inflammation

Clinical and Experimental Immunology

Volumn 110, Issue 3, 1997, Pages 485-491

  Baram, D ^b   Rashkovsky, M ^b   Hershkoviz, R ^b   Drucker, I ^b   Reshef, T ^b   Ben Shitrit, S ^b   Mekori, Y A ^a  

^a MEIR MEDICAL CENTER   (Israel)

^b NONE

Author keywords

Heparin; Low molecular weight; Mast cell; Tumour necrosis factor alpha

Indexed keywords

INTERLEUKIN 4; LOW MOLECULAR WEIGHT HEPARIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ARTICLE; CELL INFILTRATION; DRUG EFFECT; HISTAMINE RELEASE; IMMUNOMODULATION; MAST CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKIN ALLERGY;

EID: 0030833072     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.1997.4541471.x     Document Type: Article

References (34)

1. Hahnenberger R, Jakobson AM, Ansari A, Wehler T, Svahn CM, Lindhal V. Low sulfated oligosaccharides derived from heparan sulfate inhibit normal angiogenesis. Glycobiol 1993; 3:567-73.
2. Wright TC Jr, Johnstone TV, Castellot JJ, Karnovsky MJ. Inhibition of rat cervical epithelial cell growth by heparin and its reversal by EGF. J Cell Physiol 1985; 125:499-506.
3. Sahu A, Pangburn MK. Identification of multiple sites of interaction between heparin and the complement system. Mol Immunol 1993; 30:679-84.
4. Nelson RM, Cecconi O, Roberts WG, Aruffo A, Linhardt RJ, Bevilacqua MP. Heparin oligosaccharides bind L- and P- selectin and inhibit acute inflammation. Blood 1993; 82:3253-8.
5. Hogasen AK, Abrahamsen TG. Heparin suppresses lipopolysaccharide-induced monocyte production of several cytokines, but simultaneously stimulates C3 production. Thromb Res 1995; 80:179-84.
6. Steinberg BM, Grossi EA, Schwartz, DS et al. Heparin bonding of bypass circuits reduces cytokine release during cardiopulmonary bypass. Ann Thorac Surg 1995; 60:525-9.
7. Yang L, Yang YC. Heparin inhibits the expression of interleukin-11 and granulocyte-macrophage colony-stimulating factor in primate bone marrow stromal fibroblasts through mRNA destabilization. Blood 1995; 86:2526-33.
8. Lider O, Baharav E, Mekori YA et al. Suppression of experimental autoimmune diseases and prolongation of allograft survival by treatment of animals with low doses of heparins. J Clin Invest 1989; 83:752-6.
9. Lider O, Mekori YA, Miller T et al. Inhibition of T lymphocyte heparanase by heparin prevents T cell migration and T cell-mediated immunity. Eur J Immunol 1990; 20:493-9.
10. Bowler SD, Smith SM, Lavercombe PS. Heparin inhibits the immediate response to antigen in the skin and lungs of allergic subjects. Am Rev Respir Dis 1993; 147:160-3.
11. Ahmed T, Garrigo J, Danta I. Preventing bronchoconstriction in exercise-induced asthma with inhaled heparin. N Engl J Med 1993; 329:90-95.
12. Ceyhan B, Celikel T. Effect of inhaled heparin on methacholine-induced bronchial hyperreactivity. Chest 1995; 107:1009-12.
13. Garrigo J, Danta I, Ahmed T. Time course of the protective effect of inhaled heparin on exercise-induced asthma. Am J Resir Crit Care Med 1996; 153:1702-7.
14. Wolf H. Low-molecular-weight heparin. Med Clin North Am 1994; 78:733-43.
15. Carter CA, Skoutakis VA, Spiro TE et al. Enoxaparin: the low-molecular-weight heparin for prevention of postoperative thromboembolic complications. Ann Pharmacother 1993; 17:1223-30.
16. Young JD-E. Liu C-C, Butler G, Cohn ZA, Galli SJ. Identification, purification and characterization of a mast cell-associated eytolytic factor related to tumor necrosis factor. Proc Natl Acad Sci USA 1987; 84:9175-9.
17. Seldin DC, Adelman S, Austen KF et al. Homology of the rat basophilic leukemia cell and the rat mucosal mast cell. Proc Natl Acad Sci USA 1985; 82:3871-5.
18. Aridor M, Rajmilevich G, Heaven MA, Sagi-Eisenberg R. Activation of exocytosis by the heterotrimeric G protein Gi3. Science 1993; 262:1569-72.
19. Soto EO, Pecht I. A monoclonal antibody that inhibits secretion from rat basophilic leukemia cells and binds to a novel membrane component. J Immunol 1988; 141:4324-32.
20. Shore PA, Burkhalter A, Cohn VM. A method for the fluorimetric assay of histamine in tissues. J Pharmacol Exp Ther 1959; 127:182.
21. Gordon JR, Galli SJ. Mast cells as a source of both preformed and immunologically inducible TNF-α/cachectin. Nature 1990; 346:274-6.
22. Wershil BK, Wang Z-S, Gordon JR, Gall: SJ. Recruitment of neutrophils during IgE-dependent cutaneous late phase reactions in the mouse is mast cell-dependent. Partial inhibition of the reaction with antiserum against tumor necrosis factor-alpha. J Clin Invest 1991; 87:446-53.
23. Gordon JR, Burd PR, Galli SJ. Mast cells as a source of multifunctional cytokines. Immunol Today 1990; 11:458-64.
24. Lucio J, D'Brot J, Chao-Bog et al. Immunologic mast cell responses and histatnine release are attenuated by heparin. J Appl Physiol 1992; 73:1093-101.
25. Nader HB, Dietrich CP. Natural occurrence and possible biologic role of heparin. In: Lane DA, Lindahl U, eds Heparin. Chemical and biological properties. Clinical applications. New York: Edward Arnold Press 1989:81-96.
26. Gosh TK, Eis PS, Mullaney JM, Ebert CL, Gill DL. Competitive, reversible and potent antagonism of inositol, 1,4,5-triphosphate-activated calcium release by heparin. J Biol Chem 1988; 263:11075-9.
27. 3-mediated mast cell degradation? J Appl Physiol 1994; 76:893-901.
28. Pendl GG, Prieschl EE, Thumb W, Harrer NE, Auer M, Baumruker T. Effects of phosphatidylinositol-3-kinase inhibitors on degranulation and gene induction in allergically triggered mouse mast cells. Int Arch Allergy Immunol 1997; 112:392-9.
29. Resnik TR, Scott-Burden T, Baur V, Burgin M, Buhler FR. Decreased susceptibility of cultured smooth muscle cells from SHR rats to growth inhibition by heparin. J Cell Physiol 1989; 138:137-42.
30. Cahalon L, Lider O, Schor H et al. Heparin disaccharides inhibit TNF-α production by macrophages and arrest immune inflammation. Int Immunol, in press.
31. Wershil BK, Furuta GT, Lavigne JA et al. Dexamethasone or cyclosporin A suppress mast cell-leukocyte cytokine cascades. J Immunol 1995; 154:1391-8.
32. Eklund KK, Humphries DE, Xia Z et al. Glucocorticoids inhibit the cytokine-induced proliferation of mast cells, the high affinity IgE receptor-mediated expression of TNF-α, and the IL-10 induced expression of chymase. J Immunol 1997; 158:4373-80.
33. Barnes PJ, Karin M. Nuclear factor-kB - a pivotal transcription factor in chronic inflammatory diseases. N Eng J Med 1997; 336:1066-71.
34. Marquardt DL, Alongi JL, Walker LL. The phosphatidylinositol 3-kinase inhibitor Wortmanin blocks mast cell exocytosis but not IL-6 production. J Immunol 1996; 156:1942-5.